Log on / register
Feedback
|
Support
|
My details
home
|
journals A-Z
|
subject areas
|
advanced search
|
authors
|
reviewers
|
libraries
|
about
|
my BioMed Central
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L
Breast Cancer Res
2007,
9
:R87
[
Full text
]
[
PubMed
]
[
Related articles
]
[
Cited on BioMed Central
]
printer friendly
20 per page
50 per page
200 per page
500 per page
selected items
abstract
no abstract
any time period
7 Days
14 Days
30 Days
60 Days
90 Days
180 Days
1 Year
all 1 results
this page
selected items
to
Endnote (no abstracts)
Endnote + abstracts
Ref. Manager (no abstracts)
Ref. Manager + abstracts
RefWorks (no abstracts)
RefWorks + abstracts
BibTeX (no abstracts)
BibTeX + abstracts
ProCite (no abstracts)
ProCite + abstracts
[
Help
]
BioMed Central articles that cite the above article:
1.
Review
Molecular targeted therapies for breast cancer treatment
Schlotter CM, Vogt U, Allgayer H, Brandt B
Breast Cancer Research
2008,
10
:211
(24 July 2008)
[
Full text
]
[
PubMed Central
]
[
PubMed
]
[
Related articles
]
You can also
check ISI Web of Science
for additional citations (subscription required)
printer friendly
20 per page
50 per page
200 per page
500 per page
selected items
abstract
no abstract
any time period
7 Days
14 Days
30 Days
60 Days
90 Days
180 Days
1 Year
all 1 results
this page
selected items
to
Endnote (no abstracts)
Endnote + abstracts
Ref. Manager (no abstracts)
Ref. Manager + abstracts
RefWorks (no abstracts)
RefWorks + abstracts
BibTeX (no abstracts)
BibTeX + abstracts
ProCite (no abstracts)
ProCite + abstracts
[
Help
]
Terms and Conditions
Privacy statement
Information for advertisers
Jobs at BMC
Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of
Springer Science+Business Media
.